News

The study aimed at assessing the safety, tolerability and pharmacokinetics of a single administration of BL-1021 at doses between 10mg and 80mg. The preliminary modeling of the pharmacokinetic

SASPject PT1.2 is an antibiotic protein technology that offers a new approach to treat serious life-threatening bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA). RapidFACT will be used to

Discovered by Otsuka, OPA-6566 is an ophthalmic solution indicated to reduce intraocular pressure in open-angle glaucoma (OAG) or ocular hypertension patients The trial aims to evaluate the safety,

With the initiation of this trial, Abbott has paid a $10m milestone payment to Neurocrine. Neurocrine president and CEO Kevin Gorman said they are pleased that their collaboration

CompleoTRT’s delivery technology is designed to provide patients with the therapeutic effect of supplementing testosterone levels while doing so with a small amount of drug in the form

Viocare provides nutrition-based technology platforms for community, corporate and health care provided wellness programs. DSM CIO Rob van Leen said their investment in Viocare in conjunction with the

Quantum trial will evaluate interferon-free regimens of PSI-7977 400mg QD and PSI-938 300mg QD with and without ribavirin over 12 or 24 weeks in patients with HCV who

Vitamin Code formulas contain live enzymes and probiotics. Primal Defense Ultra is a probiotic formula delivered via UltraZorbe capsules and is packaged in the BioProtect Packaging System. Garden

ACE-536 is being developed as a treatment of anemia in a global collaboration with Celgene Corporation. The trial aims to evaluate the tolerability, pharmacodynamics, safety and pharmacokinetics of